We analyzed BrM-free survival (Figure 2A), the number of months from diagnosis of primary tumor to diagnosis of brain metastasis, and we correlated with patients according to whether the tumors were TNBC (bottom-right panel) or expressed ErbB2 (bottom-left panel), FN14 (upper-left panel) or GRP94 (upper-right panel). This evidence concerns the gene ERBB2 and neoplasm.